---
document_datetime: 2023-09-21 17:07:37
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/isentress-epar-procedural-steps-taken-authorisation_en.pdf
document_name: isentress-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5414148
conversion_datetime: 2025-12-22 10:01:50.597198
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Merck Sharp &amp; Dohme Ltd. submitted on 25 April 2007 an application for Marketing Authorisation to the European Medicines Agency (EMEA) for ISENTRESS, through the centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMEA/CHMP on 18 October 2006.

The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application

The  application  submitted  is  a  complete  dossier  composed  of  administrative  information,  complete quality  data,  non-clinical  and  clinical  data  based  on  applicants'  own  tests  and  studies  and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

## Scientific Advice:

The applicant received Scientific Advice from the CHMP on 29 July 2005 and on 29 September 2006. The Scientific Advice pertained to quality, non-clinical and clinical aspects of the dossier.

## Licensing status:

A new application was filed in the following countries: USA.

The product was not licensed in any country at the time of submission of the application.

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: I. Hudson

Co-Rapporteur: P. Demolis

## 2. Steps taken for the assessment of the product

- The application was received by the EMEA on 25 April 2007.
- The procedure started on 23 May 2007.
- Accelerated Assessment procedure was agreed-upon by CHMP on 26 April 2007.
- The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  26  July 2007. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 6 August 2007.
- During the meeting on 17-20 September 2007, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 17 September 2007.
- During the meeting on 17-20 September 2007, the CHMP agreed to a request from the applicant for a 1 month clock stop to submit responses to the List of Questions.
- The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  22 October 2007.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 1 November 2007.
- During  the  meeting  on  12-15  November  2007,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting  a  conditional  Marketing  Authorisation  to  ISENTRESS  on  15  November  2007.  In accordance  with  Article  3(2)  of  Regulation  (EC)  507/2006  the  CHMP  in  its  opinion  has proposed  a  conditional  Marketing  Authorisation  in  accordance  with  Article  6  of  Regulation (EC) 726/2004 after having consulted with the applicant. The applicant provided the letter of

<div style=\"page-break-after: always\"></div>

undertaking on the specific obligations and follow-up measures to be fulfilled post-authorisation on 13 November 2007.

- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 20 December 2007.